Clinical Trials Logo

Filter by:
NCT ID: NCT05977283 Recruiting - Hepatitis B Clinical Trials

HBsAg Declined Patients Follow-up Study

Start date: May 11, 2023
Phase:
Study type: Observational

The goal of this observational study is to prospectively follow chronic hepatitis B patients who had HBsAg decline in the past 12 months prior to screening. The main question it aims to answer are: - Describe treatment pattern and its impact on HBsAg loss in hepatitis B patients who had HBsAg decline in past 12 months due to any reason (with or without new molecular entities therapy). Participants will be followed up for 36 months after enrollment and may be extended upon expiration according to study objectives.

NCT ID: NCT05977257 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

VitaFlow® Transcatheter Aortic Valve Replacement System Pre-market Trial Long Term Follow Up (VITAL)

VITAL
Start date: July 30, 2023
Phase:
Study type: Observational

This study is an observational study to evaluate the long-term safety and effectiveness of the valve system.

NCT ID: NCT05977114 Recruiting - Family Relations Clinical Trials

4Rs for a Better Family

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the effects of a family conflict intervention in Chinese New Arrival families in Hong Kong. The main questions it aims to answer are: - Is the family conflict intervention group more effective to improve adaptive parent-child conflict resolution skills compared to the control group? - Is the family conflict intervention group more effective to reduce parent-child conflicts compared to the control group? - Is the family conflict intervention group more effective to improve adaptive parental conflict resolution skills compared to the control group? - Is the family conflict intervention group more effective to enhance family harmony compared to the control group? - Is the family conflict intervention group more effective to enhance family resilience compared to the control group? Participants will be randomly assigned to one of the two groups: the family conflict intervention group and the handcraft-making group. For each group, parents will participate in 3 sessions independently, children will participate in 2 sessions independently, and parents and children will jointly participate in 1 session. Each session takes around 2 hours, and it takes 4 weeks to complete the full intervention. The family conflict intervention sessions include an introduction to the occurrence of family conflicts, communication skills training to prevent and address conflicts, and role play to practice the skills, etc. Researchers will compare the family conflict intervention group and the handcraft-making group to see if the family conflict intervention group is effective in promoting conflict resolution skills, reducing family conflicts, and enhancing family resilience.

NCT ID: NCT05977101 Recruiting - SARS-CoV-2 Clinical Trials

The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects

Start date: December 17, 2021
Phase: N/A
Study type: Interventional

This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 72 healthy subjects based on inclusion and exclusion criteria. Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing. 14 days after the last dose, subjects will return to the study Center for blood samples, left nasal swabs, and throat swabs to be collected for drug concentration, immunotoxicity, and safety laboratory indicators (routine blood and biochemistry). To evaluate the safety and tolerability of MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray in healthy subjects, and to evaluate its serum concentrations and nasal and pharyngeal swab concentrations by comparing the test results of different cotillaries.

NCT ID: NCT05976997 Recruiting - Clinical trials for Newly Diagnosed Peripheral T-cell Lymphoma

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Start date: May 8, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.

NCT ID: NCT05976906 Recruiting - Clinical trials for Advanced Solid Tumors

Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, multi-center, phase I study to evaluate the safety, tolerability, preliminary efficacy, pharmacodynamics and immunogenicity of universal chimeric natural killer receptor modified T-cells (CNK-UT) targeting NKG2D-Ligands and NCR2-Ligands with or without lymphodepletion in advanced solid tumors.

NCT ID: NCT05976620 Recruiting - Breast Tumors Clinical Trials

Clinical Study of 18F-FAPI-RGD in Breast Tumors

Start date: June 20, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in Breast Tumors. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.

NCT ID: NCT05976607 Recruiting - Renal Tumor Clinical Trials

Clinical Study of 18F -FAPI-RGD in Renal Tumor

Start date: June 20, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in Renal Tumor. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.

NCT ID: NCT05976594 Recruiting - Hepatitis E Clinical Trials

Long-term Effectiveness of a Recombinant Hepatitis E Vaccine

Start date: August 12, 2023
Phase:
Study type: Observational

This test-negative study is designed to evaluate the long-term effectiveness of hepatitis E vaccine (Hecolin®) and to explore the prevalence of rat hepatitis E in Dongtai City.

NCT ID: NCT05976568 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Start date: September 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.